14 results about "Malarial infection" patented technology

Provided is a subject measurement device capable of efficiently performing a subject inspection service including an inspection of malaria infection. A subject measurement device for measuring a subject collected from a subject includes: a measurement unit for preparing a measurement sample from the subject and a reagent and detecting at least an optical signal corresponding to cells in the measurement sample; and an analysis means for analyzing the cells on the basis of the measurement of the subject by the measurement means. The measurement unit is capable of selectively performing a plurality of measurement operations on a subject. The plurality of measurement operations include: a first measurement operation in which a subject is measured using a first reagent containing a first fluorescent dye for staining white blood cells for classification of white blood cells, and a second measurement operation in which the subject is measured using a second reagent containing a second fluorescent dye for staining white blood cells for classification of white blood cells; a second measurement operation in which the subject is measured using a second reagent containing a second fluorescent dye that stains cells suspected of being infected with malaria; and a third measurement operation in which the subject is measured using the first reagent and the second reagent.

Disclosed is a blood analyzer including: a first sample preparation unit configured to prepare, from a blood sample, a first measurement sample for measuring a red blood cell infected with malaria; a second sample preparation unit configured to prepare, from the blood sample, a second measurement sample for measuring intrinsic fluorescence of a red blood cell; a light source unit configured to apply light to the first and the second measurement samples; a detection unit configured to detect fluorescence and scattered light generated from the first measurement sample to which light has been applied, and detect intrinsic fluorescence generated from the second measurement sample to which light has been applied; and an information processing unit configured to generate information about malaria infection based on fluorescence and scattered light detected from the first measurement sample, and generate information about iron-deficiency anemia based on intrinsic fluorescence detected from the second measurement sample.

Disclosed is a sample measurement apparatus configured to measure a sample collected from a subject, comprising: a measurement unit configured to execute a measurement of the sample, the measurement including preparing a measurement sample from the sample and a reagent and detecting at least optical signals corresponding to cells in the measurement sample; and an analysis unit configured to analyze the cells at least according to the optical signals detected in the measurement of the sample by the measurement unit, wherein the measurement unit is operable to selectively perform a plurality of measurement operations including: (1) a first measurement operation that includes the measurement of the sample using a first reagent containing a first fluorescent dye that stains leukocytes for classification of leukocytes; (2) a second measurement operation that includes the measurement of the sample using a second reagent containing a second fluorescent dye that stains cells suspected of malaria infection; and (3) a third measurement operation that includes the measurement of the sample using the first reagent and the second reagent.

The present invention provides novel compositions for treating malarial infections comprising prodrugs of ELQ-300 and an oil, wherein the composition can further comprise benzyl alcohol and / or benzyl benzoate, and methods of use thereof.

The present disclosure relates to a composition for inhibiting cross-species infection of malaria caused by Plasmodium vivax in a subject. Preferably, the disclosed compositions are prepared in the form of a vaccine comprising: a plurality of polynucleotides, each of the plurality of polynucleotides comprising a sequence as set forth in SEQ ID No.1 or SEQ ID No.2, expressed in the subject for inducing an immune response responsive to a malaria infection thereof; a liquid phase of lipid nanoparticles, the liquid phase of lipid nanoparticles configured to form a protective layer, the protective layer encapsulating a plurality of polynucleotides within the protective layer; and a pharmaceutically acceptable adjuvant.

Methods of treating and preventing malaria infection, comprising administering a therapeutically effective amount of cell permeability modulating therapy are provided herein.

The present disclosure relates to compositions and methods for treating and / or preventing malarial infections. In some embodiments, the present disclosure provides recombinant antibodies and compositions thereof for treating and / or preventing a malarial infection. The present disclosure also provides methods of using the recombinant antibodies and compositions thereof to treat and / or prevent a malarial infection.

This invention relates to compounds, compositions and methods for preventing or treating malaria by modulating immune responses through Killer-specific Secretory Protein 37 (Ksp37). The invention provides for the administration of Ksp37, or stimulation of endogenous Ksp37 production using polar compounds such as DMF or DMSO, to increase Ksp37 levels in a subject to therapeutically effective concentrations. Elevated Ksp37 enhances cytotoxic CD8+ T-cell and NK-cell activity, supports cytokine balance, and improves immune clearance of Plasmodium parasites during both liver and blood stages. These approaches promote targeted immune activation, reduce parasite survival, and improve host protection against malaria infection.

The present invention relates to a malaria vaccine composition designed to elicit an immune response against Plasmodium falciparum by providing proteins or amino acid sequences, including PfGBP130 or PfGBP130-A surface antigen sequences. Upon administration to a human subject, the vaccine composition induces the production of specific anti-malaria antibodies. These antibodies are configured to inhibit the invasion of red blood cells by Plasmodium falciparum parasites and / or the antibodies binding to the antigens can cause the death of the parasites within red blood cells, thereby offering a preventive and / or therapeutic effect against malaria. The composition aims to enhance the immune defense mechanism in humans, reducing the incidence and severity of malaria infections by targeting critical stages of the parasite's lifecycle.

Methods of treating and preventing malaria infection, comprising administering a therapeutically effective amount of cell permeability modulating therapy are provided herein. Among other things, the present disclosure provides parameters that define subjects who are relatively susceptible or resistant to malaria infection. The present disclosure also provides therapeutic strategies for increasing malarial resistance and / or imparting a resistant state on subjects.

The present invention relates to a malaria vaccine composition designed to elicit an immune response against Plasmodium falciparum by providing proteins or amino acid sequences, including PfGBP130 or PfGBP130-A surface antigen sequences. Upon administration to a human subject, the vaccine composition induces the production of specific anti-malaria antibodies. These antibodies are configured to inhibit the invasion of red blood cells by Plasmodium falciparum parasites and / or the antibodies binding to the antigens can cause the death of the parasites within red blood cells, thereby offering a preventive and / or therapeutic effect against malaria. The composition aims to enhance the immune defense mechanism in humans, reducing the incidence and severity of malaria infections by targeting critical stages of the parasite's lifecycle.

An electronic device to which a machine learning ensemble model is applicable, according to an exemplary embodiment of the present disclosure, may comprise: a first model neural-network-trained on the basis of training images; a second model trained on the basis of training test data; a third model using voting based on a plurality of statistical methodologies so as to output the infection probability of malaria infection; and a processor, which inputs, into the first model, a blood image to be tested, uses the first model to make a primary determination of malaria infection about the blood image, inputs, into the second model, blood data to be tested, uses the second model to make a secondary determination of malaria infection about the blood data, and uses the third model to output the malaria infection probability.

The present invention relates to a component for a malaria vaccine comprising: a) an immunogenic particle RTS,S and / or b) an immunogenic particle derived from the CS protein of one or more P. vivax strains and S antigen from Hepatitis B and optionally unfused S antigen, or c) an immunogenic particle comprising RTS, CSV-S and optionally unfused S antigen, and d) a stabilizing agent comprising a stabilizing agent with at least one thiol functional group, or mixtures thereof. Methods for preparing the component, its use in medicine, particularly in the prevention of malarial infections, compositions / vaccines containing the component and use of the latter, particularly in therapy are also disclosed.